Liprotamase (Sollpura) for exocrine pancreatic insufficiency due to cystic fibrosis


featured image
Year: 2017

Liprotamase is a new drug for the treatment of exocrine pancreatic insufficiency (EPI), a condition where the pancreas does not produce enough enzymes for digesting fat, carbohydrates and proteins. EPI is common in patients who have cystic fibrosis (CF), which is the most common inherited disease in the UK.Liprotamase works by replacing the lacking pancreatic enzyme, improving digestion and the absorption of nutrients from food. Other forms of pancreatic enzyme replacement therapy are available for use, but they do not work well in some patients with CF, require a large number of capsules to be taken, and are animal derived. Liprotamase would provide a new, non-animal derived form of therapy for these patients.